CONFERENCE UPDATE: EHA 2021

A+AVD as a desirable treatment option for patients with previously untreated stage III/IV CHL: A 5-year update of the phase 3 ECHELON-1 study

HEMATOLOGY
24 Sep 2021

Get access to our exclusive articles.
Related Articles

cHL subtypes - Clinical and prognostic significance

In the 64th American Society of Hematology (ASH) Annual Meeting and Exposition 2022, Dr. Stefan K. Alig, from Stanford University, the United States, shared his group’s study on the distinct molecular subtypes of classic Hodgkin lymphoma (cHL) identified by comprehensive noninvasive profiling.1 Pat
HEMATOLOGY
23 Feb 2023

Brentuximab vedotin serves as a viable option to combine with chemotherapy for advanced stage Hodgkin lymphoma

The combination treatment approach of chemotherapy and radiotherapy has significantly improved the survival outcomes of patients with Hodgkin lymphoma (HL) over the past several decades.1 Whereas the conventional frontline therapies, such as ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), c
HEMATOLOGY ONCOLOGY
31 Dec 2020

Advanced-stage Hodgkin lymphoma in an elderly patient: A case report highlighting the efficacy of brentuximab vedotin treatment

Hodgkin lymphoma (HL) is an aggressive hematological malignancy, with around 70 new cases being reported per year in Hong Kong.1 The incidence rate for HL among people aged 65 or above in Hong Kong is 1.6 per 100,000 persons.1

HEMATOLOGY ONCOLOGY
30 Jun 2020